Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank36
3Y CAGR+29.8%
5Y CAGR-60.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+29.8%/yr
vs -32.4%/yr prior
5Y CAGR
-60.1%/yr
Recent acceleration
Acceleration
+62.3pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 3.75% |
| 2024 | 25.01% |
| 2023 | 14.76% |
| 2022 | 1.72% |
| 2021 | 5.90% |
| 2020 | 370.17% |
| 2019 | -81.26% |
| 2018 | 8.24% |
| 2017 | -30.28% |
| 2016 | -10.40% |